Overview Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indicator: Together with chemotherapy, with the treatment of adult patients with locally recurrent unresectable or metastatic triple-destructive breast cancer which have not obtained prior chemotherapy for metastatic disease and whose tumours express programmed mobile Dying-ligand 1 (blended beneficial rating ≥ 10) as dete... https://janeb690cfh6.activablog.com/profile